2-(吗啉-4-基甲基)苯硼酸 | 223433-45-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(吗啉-4-基甲基)苯硼酸
• 中文别名: 2-吗啉甲基苯硼酸；2-(吗啉甲基)苯基硼酸；B-[2-(4-吗啉甲基)苯基]硼酸
• 英文名称: (2-(morpholin-4-ylmethyl)phenyl)boronic acid
• 英文别名: [2-(morpholin-4-ylmethyl)phenyl]boronic acid；2-(morpholinomethyl)phenylboronic acid；ortho-(N-morpholinomethyl)-benzeneboronic acid；(2-morpholin-4-ylmethyl-phenyl)-boronic acid；2-morpholinomethyl-benzeneboronic acid；morpholinylbenzylamine-2-boronic acid
• CAS: 223433-45-2
• 化学式: C₁₁H₁₆BNO₃
• 分子量: 221.064
• InChiKey: DFBBOZSTIQMBLF-UHFFFAOYSA-N

物化性质

• 熔点：
  222-226°C
• 沸点：
  394.1±52.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  52.9
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(Morpholinomethyl)phenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H315: Causes skin irritation
H318: Causes serious eye damage
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Morpholinomethyl)phenylboronic acid
CAS number: 223433-45-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H16BNO3
Molecular weight: 221.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-bromophenyl)-4-hydroxy-1,6-naphthyridine-3-carbonitrile 、 2-(吗啉-4-基甲基)苯硼酸 在 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 potassium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.5h， 以68%的产率得到4-hydroxy-2-[2'-(morpholin-4-ylmethyl)biphenyl-4-yl]-1,6-naphthyridine-3-carbonitrile
  参考文献：
  名称：

  Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors

  摘要：

  A series of 1,6-naphthyridine-based compounds was synthesized as potent phosphodiesterase 10A (PDE10A) inhibitors. Structure-based chemical modifications of the discovered chemotype served to further improve potency and selectivity over DHODH, laying the foundation for future optimization efforts. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.046
• 作为产物：
  描述：

  1,3-dihydro-1-hydroxy-3-(4-morpholinyl)-2,1-benzoxaborole 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 0.33h， 以22%的产率得到2-(羟甲基)苯硼酸环状单酯
  参考文献：
  名称：

  Amination-reduction reaction as simple protocol for potential boronic molecular receptors. Insight in supramolecular structure directed by weak interactions

  摘要：

  标题：摘要 在包含（2-甲酰基苯基）硼酸和吗啉的模型体系中，研究了氨基化还原反应中潜在的分子受体的合成。确定了3-氨基取代苯并硼酮是合成的中间体，未取代苯并硼酮是由于起始物质还原而产生的副产物。对起始物质和中间体苯并硼酮的反应性的洞察使2-（氨甲基）苯硼酸合成的产率显著提高。重新确定了2-（哌啶甲基）苯硼酸的固态结构，并给出了该分子和晶体的描述。通过几何和Hirshfeld表面分析，识别和审查了由弱的C-H…O和C-H…π相互作用引导的超分子层结构。

  DOI：

  10.2478/s11532-010-0142-8

文献信息

• Pyrimidine Derivatives As HSP90 Inhibitors
  申请人：Chessari Gianni

  公开号：US20090215777A1

  公开（公告）日：2009-08-27

  The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR 3 ; R 1 is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of which up to two ring members may be heteroatoms selected from N, O and S and the remainder are carbon atoms, the carbocyclic or heterocyclic ring being optionally substituted by one or more substituent groups independently selected from R 10 ; and R 2 , R 3 and R 10 are as defined in the claims.

  该发明提供了一种化合物，用作Hsp90的抑制剂，该化合物具有以下式（I）：或其盐、互变异构体、溶剂合物或N-氧化物；其中：A为N或CR基团；R1为由5至10个环成员组成的单环或双环碳环或杂环，其中最多两个环成员可以是从N、O和S中选择的杂原子，其余为碳原子，碳环或杂环可以选择地被一个或多个取代基独立地选择自R10的取代基取代；而R2、R3和R10如权利要求中所定义。
• [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
  申请人：ABBVIE INC

  公开号：WO2013097601A1

  公开（公告）日：2013-07-04

  The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, X1, X2, Y1, L1, G1, Rx, and Ry have any of the values defined thereof in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

  本发明提供了一种具有以下式（I）的化合物，其中A1、A2、A3、A4、X1、X2、Y1、L1、G1、Rx和Ry在规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病症的药物，包括炎症性疾病、癌症和艾滋病的药剂。还提供了包含一种或多种式（I）化合物的药物组合物。
• [DE] VERWENDUNG VON SUBSTITUIERTEN 2-PHENYLBENZIMIDAZOLEN ALS ARZNEIMITTEL<br/>[EN] USE OF SUBSTITUTED 2-PHENYLBENZIMIDAZOLES AS MEDICAMENTS<br/>[FR] UTILISATION DE 2-PHENYLBENZIMIDAZOLES SUBSTITUES EN TANT QUE MEDICAMENTS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2004062663A1

  公开（公告）日：2004-07-29

  Die vorliegende Erfindung betrifft die Verwendung eines substituierten 2-Phenylbenzimidazols der Formel (I), worin R1, R2, R3, R4, R5 und m die in den Ansprüchen angegebenen Bedeutungen aufweisen, für die Herstellung eines Medikamentes zur Behandlung oder Vorbeugung von Krankheiten, bei denen Glucagon Rezeptoren beteiligt sind, sowie neue Verbindungen der Formel (I), worin R1 ein Dehydroabietyl-Rest der Formel (II) ist.

  这项发明涉及使用式（I）的取代2-苯基苯并咪唑，其中R1、R2、R3、R4、R5和m具有权利要求中所述的含义，用于制备一种药物，用于治疗或预防涉及胰高血糖素受体的疾病，以及式（I）中R1为式（II）的脱氢松香烯基团的新化合物。
• PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES
  申请人：Eickhoff Jan

  公开号：US20130079345A1

  公开（公告）日：2013-03-28

  The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.

  本发明涉及二取代三嗪衍生物和/或其药学上可接受的盐，这些衍生物作为药物活性剂的使用，特别是用于预防和/或治疗传染病，包括机会性疾病、免疫疾病、自身免疫性疾病、心血管疾病、细胞增殖性疾病、炎症、勃起功能障碍和中风，以及至少包含其中一种二取代三嗪衍生物和/或其药学上可接受的盐的制药组合物。此外，本发明涉及使用所述二取代三嗪衍生物作为蛋白激酶抑制剂的用途。
• Systematic Structural Tuning Yields Hydrazonyl Sultones for Faster Bioorthogonal Protein Modification**
  作者：Ming Fang、Gangam Srikanth Kumar、Qing Lin

  DOI：10.1002/cbic.202300398

  日期：2023.7.17

  A robust HS: Systematic studies of substituent effect yield hydrazonyl sultones (HS) that permit autonomous access of highly reactive nitrile imines through tautomerization to afford faster bioorthogonal modification of a nanobody carrying a strained alkyne, bicyclo[6.1.0]non-4-yn-9-ylmethanol.

  稳健的 HS ：对取代基效应的系统研究产生腙磺内酯 (HS)，允许通过互变异构自主获得高反应性腈亚胺，从而对携带应变炔、双环[6.1.0]non-4-yn 的纳米体进行更快的生物正交修饰-9-基甲醇。